AI assistant
CAMBIUM BIO LIMITED — Capital/Financing Update 2021
Aug 8, 2021
64666_rns_2021-08-08_9122e3e7-8c0e-4a16-9f65-a3296fc5567e.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [160 x 33] intentionally omitted <==
ASX Announcement
9 August 2021
Lapse of Unlisted Share Options
Regeneus Ltd (ASX: RGS) ( Regeneus or the Company ), a clinical-stage regenerative medicine company, advises that the following unlisted share options granted pursuant to Regeneus’s option share trust plan have lapsed with the recent resignation of Sandra McIntosh:
| cent resignation of | Sandra McIntosh: | |
|---|---|---|
| Lapsed Options | Exerciseprice | Expiry Date |
| 600,000 | $0.10 | 30-Sep-24 |
| 1,401,000 | $0.10 | 30-Jun-25 |
The total number of options remaining on issue following the lapse of the above options are as follows:
| Number of Options |
Exerciseprice | Expiry Date |
|---|---|---|
| 1,250,000 | $0.20 | 31-Jan-24 |
| 400,000 | $0.10 | 30-Sep-24 |
| 1,980,770 | $0.10 | 30-Jun-25 |
| 1,029,500 | $0.14 | 31-Aug-25 |
| 1,000,000 | $0.1075 | 31-Aug-25 |
| 5,000,000 | $0.10 | 24-May-26 |
| 5,000,000 | $0.10 | 24-May-26 |
| 15,000,000 | $0.10 | 24-May-26 |
-ENDS-
About Regeneus
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.
Authorisation & Additional information Investor and Media Contact This announcement was authorised by the Board WE Communications of Directors of Regeneus Ltd T: 02 9237 2805 E: [email protected]
2 Paddington Street, Paddington, NSW 2021 Ph: +61 2 9499 8010 • www.regeneus.com.au • ABN 13 127 035 358